Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ABL DiagnosticsXPAR:ABLD +2.50%49 Cyclically Adjusted PB Ratio is 1.15 as of Jul. 30, 2026, which is 8% below its 10-year median of 1.25. GuruFocus rates XPAR:ABLD with a GF Score™ of 49/100 and a GF Value™ of €7.96 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 356 Healthcare Providers & Services companies, ABL Diagnostics ranks better than 66.85% on this metric.
The historical rank and industry rank for ABL Diagnostics's Cyclically Adjusted PB Ratio or its related term are showing as below:
XPAR:ABLD'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.41 Med: 1.25 Max: 5.14
Current: 1.17
During the past 13 years, ABL Diagnostics's highest Cyclically Adjusted PB Ratio was 5.14. The lowest was 0.41. And the median was 1.25.
XPAR:ABLD's Cyclically Adjusted PB Ratio is ranked better than 66.85% of 356
companies
in the Healthcare Providers & Services industry
Industry Median: 1.84
vs XPAR:ABLD: 1.17
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
ABL Diagnostics's adjusted book value per share data of for the fiscal year that ended in Dec25 was €0.475. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.13 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
ABL Diagnostics (XPAR:ABLD) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
ABL Diagnostics Cyclically Adjusted PB Ratio Related Terms
ABL Diagnostics Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics Cyclically Adjusted PB Ratio Chart
XPAR:ABLD vs VEEV, BTSG, HQY: Cyclically Adjusted PB Ratio Comparison
For the Health Information Services subindustry, ABL Diagnostics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics Cyclically Adjusted PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's Cyclically Adjusted PB Ratio falls into.
ABL Diagnostics Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
ABL Diagnostics's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 1.15 mean?
ABL Diagnostics (XPAR:ABLD) has a Cyclically Adjusted PB Ratio of 1.15 as of Jul. 30, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on ABL Diagnostics and its competitors. This is near median its historical median of 1.25. Over the past decade, ABL Diagnostics' Cyclically Adjusted PB Ratio has ranged from 0.41 to 5.14. According to the industry distribution chart, ABL Diagnostics ranks #118 out of 356 companies in the Healthcare Providers & Services industry, placing it in the top 33.1%.
Is ABL Diagnostics' Cyclically Adjusted PB Ratio too high?
ABL Diagnostics' current Cyclically Adjusted PB Ratio of 1.15 is near median its 10-year median of 1.25. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 5.14. The Healthcare Providers & Services industry median Cyclically Adjusted PB Ratio is 1.84. ABL Diagnostics' value of 1.15 is 37.5% below this industry median. Based on the distribution chart, ABL Diagnostics ranks #118 out of 356 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 49/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Cyclically Adjusted PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #118 out of 356 companies for Cyclically Adjusted PB Ratio. This puts ABL Diagnostics in the upper half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.84. ABL Diagnostics' value of 1.15 is 37.5% below this benchmark. Historically, ABL Diagnostics' own Cyclically Adjusted PB Ratio has ranged from 0.41 to 5.14 over the past decade. While the company's 10-year median is 1.25 vs. the industry median of 1.84, ABL Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Healthcare Providers & Services company?
The median Cyclically Adjusted PB Ratio among Healthcare Providers & Services companies is 1.84, based on 356 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current Cyclically Adjusted PB Ratio of 1.15 is 37.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median Cyclically Adjusted PB Ratio is 1.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current Cyclically Adjusted PB Ratio is 1.15, which is near median its own 10-year median of 1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.96, compared to a current price of €2.46 — trading 69.1% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 1.15, which is near median its 10-year median of 1.25 and 37.5% below the Healthcare Providers & Services industry median of 1.84. ABL Diagnostics' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Cyclically Adjusted PB Ratio is 1.15 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.46 is trading 69.1% below its estimated GF Value™ of €7.96.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
Cyclically Adjusted PB Ratio: 1.15 (near median its 10-year median of 1.25)
GF Value™: €7.96 vs. price of €2.46 (69.1% below fair value)
Industry Position: 37.5% below the Healthcare Providers & Services median (#118 of 356)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
49GF Score
Get the complete analysis for XPAR:ABLD
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
